(Q39627463)

13 September 2017

title

Natural variation in drug susceptibility to HCV polymerase inhibitors in treatment-naïve HCV patient isolates (English)

1 reference

13 September 2017

S-C C Sun

1

1 reference

13 September 2017

A Bae

2

1 reference

13 September 2017

X Qi

3

1 reference

13 September 2017

J Harris

4

1 reference

13 September 2017

K A Wong

5

1 reference

13 September 2017

M D Miller

6

1 reference

13 September 2017

H Mo

7

1 reference

13 September 2017

publication date

25 November 2010

1 reference

Journal of Viral Hepatitis

13 September 2017

published in

1 reference

13 September 2017

volume

18

1 reference

13 September 2017

issue

12

1 reference

13 September 2017

page(s)

861-870

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01396.X

Past, present, and future hepatitis C treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01396.X

Review article: pegylated interferons: chemical and clinical differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01396.X

Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01396.X

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01396.X

SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01396.X

Mechanism of Activation of -D-2'-Deoxy-2'-Fluoro-2'-C-Methylcytidine and Inhibition of Hepatitis C Virus NS5B RNA Polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01396.X

Selected Replicon Variants with Low-Level In Vitro Resistance to the Hepatitis C Virus NS5B Polymerase Inhibitor PSI-6130 Lack Cross-Resistance with R1479

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01396.X

Crystallographic Identification of a Noncompetitive Inhibitor Binding Site on the Hepatitis C Virus NS5B RNA Polymerase Enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01396.X

Non-nucleoside inhibitors of the HCV polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01396.X

Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01396.X

Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01396.X

HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01396.X

Selection and Characterization of Hepatitis C Virus Replicons Dually Resistant to the Polymerase and Protease Inhibitors HCV-796 and Boceprevir (SCH 503034)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01396.X

Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01396.X

Evaluation of VCH-759 monotherapy in hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01396.X

In Vitro Resistance Study of AG-021541, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01396.X

Preclinical Characterization of PF-00868554, a Potent Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01396.X

Wide range of quasispecies diversity during primary hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01396.X

Viral heterogeneity of the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01396.X

The origin and evolution of hepatitis viruses in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01396.X

Sequences in the 5' nontranslated region of hepatitis C virus required for RNA replication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01396.X

Viral and Cellular Determinants of Hepatitis C Virus RNA Replication in Cell Culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01396.X

A replicon-based shuttle vector system for assessing the phenotype of HCV NS5B polymerase genes isolated from patient populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01396.X

Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01396.X

10.1111/J.1365-2893.2010.01396.X

21 January 2018

Identifiers

DOI

1 reference

13 September 2017

1 reference